Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism
Suresh R Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Vighnesh Jadhav, Sandip Palode, Ramchandra Ranvir, Ashvin Patel, Rajesh Sundar, Hiren Patel, Mukul R Jain, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad 382213, Gujarat, India
Author contributions: Giri SR, Bhoi B, and Jain MR designed and coordinated the study, drafted the manuscript; Giri SR, Sundar R, and Jain MR supervised the project and were responsible for project administration and funding acquisition; Bhoi B, Trivedi C, Rath A, Jadhav V, Palode S, Patel A, and Patel H performed the experiments, acquired the data, and conducted data analysis; Ranvir R, Patel A, Sundar R, and Patel H reviewed and interpreted the data; all authors critically reviewed the manuscript and approved the final version.
Institutional animal care and use committee statement: All animal procedures were reviewed and approved by the Institutional Animal Ethics Committee of Zydus Research Centre, Zydus Lifesciences Limited, under protocol No. ZRC/PH/BP/049/02-2K23.
Conflict-of-interest statement: All authors are employees of Zydus Lifesciences Limited, Ahmedabad, India and do not have any conflicts of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The datasets generated and analysed during the current study are available from the corresponding author upon reasonable request. No additional data are available.
Corresponding author: Suresh R Giri, PhD, Zydus Research Centre, Zydus Lifesciences Limited, Sarkhej-Bavla Highway No. 8A, Moraiya, Ahmedabad 382213, Gujarat, India.
Received: February 24, 2026
Revised: April 23, 2026
Accepted: June 15, 2026
Published online: July 27, 2026
Processing time: 157 Days and 20.3 Hours
Revised: April 23, 2026
Accepted: June 15, 2026
Published online: July 27, 2026
Processing time: 157 Days and 20.3 Hours
Core Tip
Core Tip: Alcoholic liver disease is one of the major causes of morbidity worldwide and there is an unmet need for a drug to prevent or treat this condition. Saroglitazar, which is approved in India for the treatment of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, showed beneficial effect like reduction in alanine aminotransferase, aspartate aminotransferase and hepatic triglyceride in animal model of alcoholic liver disease. Saroglitazar effectively altered the alcohol metabolism markers, thus reducing the alcohol-induced liver damage.